{"id":"W2893246991","doi":"10.1136/annrheumdis-2018-eular.5146","title":"AB0954 A randomised, double-blind trial comparing the efficacy, safety and immunogenicity of msb11022, a proposed biosimilar of adalimumab, versus adalimumab originator in patients with moderate-to-severe plaque psoriasis","year":2018,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Adalimumab; Medicine; Psoriasis Area and Severity Index; Biosimilar; Psoriatic arthritis; Tolerability; Clinical endpoint; Bioequivalence; Internal medicine; Psoriasis; Interim analysis; Clinical trial; Adverse effect; Rheumatoid arthritis; Dermatology; Pharmacokinetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002139041,0.001964241,0.004754975,0.0004673093,0.00052807,0.001360123,0.001031282,0.002773001,0.01130475],"category_scores_gemma":[0.002666194,0.00104401,0.002522534,0.0004925773,0.001933336,0.001399638,0.0006697283,0.003992252,0.002624304],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007327484,"about_ca_system_score_gemma":0.001000609,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001106345,"about_ca_topic_score_gemma":0.001485616,"domain_scores_codex":[0.9988672,0.0006133373,0.00009555628,0.000220992,0.00006120293,0.000141855],"domain_scores_gemma":[0.9986439,0.0004791139,0.0002069905,0.0001724797,0.0001103246,0.000387046],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9916233,0.001773233,0.0001310549,0.0003016812,0.0004840497,0.00001755228,0.00001433125,0.00008707073,0.001624173,0.0000840444,0.0002710635,0.003588302],"study_design_scores_gemma":[0.9785755,0.0204749,0.0002958738,0.00001246393,0.0001745737,0.00001250335,0.000005192752,0.00009236055,0.0001048109,0.00006033423,0.000185175,0.000006333882],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9769572,0.006112597,0.001375174,0.001189388,0.002813305,0.004897155,0.001665129,0.0002317492,0.004758424],"genre_scores_gemma":[0.9799848,0.002633014,0.002122504,0.00203088,0.001042609,0.004530139,0.00175129,0.00004378709,0.005861074],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01130475,"threshold_uncertainty_score":0.03781819,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05245146854743497,"score_gpt":0.3175573006045067,"score_spread":0.2651058320570717,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}